Holland Capital Invests in Curess
Amsterdam, June 20th, 2024 – Holland Capital participates in Curess, a leading organization in youth care focused on systemic family support. Through the collaboration with Holland Capital, further growth and development can be achieved.
Systemic Family Support
Curess offers specialized ambulatory youth care (such as intensive systemic guidance, ambulatory emergency help, perspective research, and co-parenting investigations) and focuses on strengthening families through practical and directly applicable assistance. Curess operates without waiting lists and can scale its operations up and down quickly, to deliver the desired care swiftly and with high quality. The organization achieves this by applying self-developed software that supports core processes (such as planning) and thus reduces administrative pressure.
Strategic Parntership
With this strategic partnership, Curess has found a partner to achieve its ambitious strategic goals.
Eddy de Bruin, CEO of Curess, states: “With the support of Holland Capital, we can realize our ambitions and help even more young people and families. With their expertise and resources, we are better equipped to significantly increase our impact in youth care. We are committed to providing the necessary support to families to learn to live together better, without waiting lists, through our dedicated professionals.”
Margot Engels, Healthcare Partner at Holland Capital, adds: “We are proud to add Curess to our portfolio. Curess provides crucial support to families in an innovative way, and we look forward to working together on their growth ambitions and further professionalization of their services. Our shared vision is to provide the best possible care and support.”
About Curess
With over 200 registered professionals, Curess offers specialized ambulatory youth care to young people and families to ensure they can live together better. By utilizing personal and innovative methods, Curess strives for a safe and supportive environment for children and their families. Curess is active in the regions of Twente, Midden-IJssel, Oost-Veluwe, Noord-Veluwe, Achterhoek, and Zuid-Drenthe
About Holland Capital
Holland Capital has been responsibly and successfully investing in promising Dutch and German SMEs with growth ambitions for over 40 years. The team understands entrepreneurship and strives for an open, sustainable, and professional relationship with the management teams of the companies they invest in, with the common goal of realizing growth. Holland Capital has offices in Amsterdam and Düsseldorf. With specialized sector teams, it focuses on the Healthcare, Technology, and Agrifood-Tech sectors. They understand the dynamics and opportunities, and have an extensive network in these sectors.
The participation in Curess fits within Holland Capital’s strategy to invest in companies that contribute to societal challenges and create value for society. With this investment, Holland Capital takes an important step in further strengthening its portfolio within the healthcare sector.
Highcare supports management buy-out Zorgzuster
Roosendaal/Maastricht, 27 November 2018 – Highcare and Ralph Smeets acquire all shares of Zorgzuster Nederland from Start People (part of USG People The Netherlands). Ralph Smeets has founded Zorgzuster in 2010. Highcare is the employment and deployment agency in the...
Holland Venture invests in WSO2 integrator Yenlo
Amsterdam, 19 November 2018 – Private Equity firm Holland Venture invests in Yenlo, the leading integration specialist on WSO2 open source middleware technology. The management and shareholders have set a target for the coming years to strengthen the growth of the...
Holland Venture sells its shares in QSight IT to KPN
Amsterdam, October 3, 2017 - On the 2nd of October, Holland Venture and the other (management) the signed the acquisition contracts to sell their shares in QSight IT to Dutch telecom and ICT provider KPN. QSight IT is a leading Dutch player in the field of...
Holland Venture invests in LivAssured to support further development of the NightWatch
A groundbreaking detection system for nocturnal epileptic attacks Amsterdam, 20 September 2018 - Investment company Holland Venture invests with Oost NL and Health Innovations Fund in LivAssured, which developed the revolutionary NightWatch in collaboration...
Holland Venture closed a new fund to support innovation in healthcare
Amsterdam, 20 September 2018 – Holland Venture closed a new healthcare innovation fund which will invest in approx. 10 Dutch healthcare start-ups, active in the field of medical devices, diagnostics and digital health. The aim of the fund is to support entrepreneurs...
Quantib presents revolutionary software for dementia and MS diagnosis support and tracking
Rotterdam, The Netherlands – August 1st 2018. Quantib, market leader in artificial intelligence tools for radiology, released a major upgrade of their dementia and MS diagnosis support software Quantib™ ND. A substantial list of new features supporting the diagnosis...
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl